PHILADELPHIA - A federal judge in Pennsylvania on May 11 granted summary judgment to the producers and distributors of Wellbutrin XL on direct and indirect purchasers' claims that the defendants illegally conspired to prevent generic versions of the drug from entering the American market by filing sham patent infringement lawsuits and a citizen petition (In re: Wellbutrin XL Antitrust Litigation, Nos. 08-2431 (direct), Nos. 08- 08-2431 (indirect), E.D. Pa.; 2012 U.S. Dist. LEXIS 66312).